Background {#Sec1}
==========

Although islet cell transplantation is effective for treating certain type 1 diabetes patients, some hurdles are inherent to this and other donor-based transplantation methods \[[@CR1]--[@CR4]\]. Two hurdles are the limited graft supply and graft rejection. One solution for islet cell transplantation could be to move from donor-harvested to stem cell-derived transplant tissue. That could involve production of pancreatic progenitor cells from human embryonic stem (hES) cells. Using stem cells in general may have some advantages compared to current islet cell transplantation. These advantages include the potential of producing stem cells in large quantities thereby eliminating the cell supply problem and possibly reducing the treatment cost per patient.

Research in that area of treatment has advanced from proof-of-principle studies in animals, to establishing controllable cell manufacturing processes, and the first clinical trials in humans \[[@CR5]--[@CR15]\]. As of 2017 clinical trials are ongoing in Canada and the United States that use a thin removable device which is implanted under the skin \[[@CR7], [@CR16]\]. This device has hES cell-derived pancreatic progenitor cells within a casing to shield the tissue from the immune system \[[@CR15]\]. Those cells are expected to mature to functional endocrine cells which secrete insulin in a glucose-dependent manner \[[@CR9], [@CR14]--[@CR16]\]. Further improvement in protection of transplant tissue could increase its viability and reduce graft rejection. The long term goal of research into beta cell replacement therapy is to reverse diabetes and completely avoid the need for immunosuppressive medication.

In 2011 Weir et al. mention, "due to the need for beta cell replacement therapy, much work has been done in the past decade to generate beta cells from a variety of cell sources" \[[@CR13]\]. However, these efforts have had mixed success. A major barrier has been in the ability to direct cell lines to differentiate towards an endocrine lineage. That process was very inefficient and most cell lines could not be used. Further, technologies used in the preservation of graftable cells, for example through cooling to very low temperatures, have advanced considerably but are still difficult and costly \[[@CR17], [@CR18]\]. Use of simpler preservation technologies makes cell tissue more perishable but experiences in standard donor-derived transplantation may point towards greater affordability of such techniques. Still, those barriers add to existing complexities associated with supply logistics, regulatory frameworks and scaling out production to multiple cell manufacturing sites \[[@CR19]\].

Given those developments and findings, stem cell-based beta cell replacement therapy is a case study for the necessity of prioritizing research resources when researching new healthcare technologies. In our study we aimed to explore the circumstances under which a stem cell-based graft tissue would be cost-effective, given its effectiveness is comparable to state of the art islet transplantation aside from immunosuppression drawbacks. Our core question is if and how such a new transplant option for beta cell replacement has a chance of being cost-effective.

Methods {#Sec2}
=======

To model the cost of hES cell-derived transplant doses we used a two part cost-effectiveness and manufacturing model (Fig. [1](#Fig1){ref-type="fig"}). This stochastic model is based on a previous treatment model of type 1 diabetes \[[@CR20]\] and the work by Simaria and colleagues \[[@CR21]\]. Presuming equal effectiveness with the current technology islet transplantation, aside from the immunosuppression drawbacks, we then ran the model to simulate marginal differences in clinical effects and costs, between the new stem cell-based technology and our comparator intensive insulin therapy. We used the models outputs to estimate the cost-effectiveness of this trial-stage therapy.Fig. 1The role of our cost estimation model within the cost-effectiveness analysis. Note that we used the explicit cost optimization model for our stem cell-based treatment only

Compared treatments {#Sec3}
-------------------

The form of beta cell replacement therapy was modeled as a series of identical re-extractable subcutaneous implant devices ('sheets'). Each of these devices contain hES-derived cells, specifically pancreatic progenitors which were modified to attain the function of beta cells. Those cells are enclosed within a casing which shields them from the immune system but allows the transport of nutrients to and hormones from the encapsulated cells \[[@CR14], [@CR15]\]. In our study we make the important assumption that this shielding effect completely removes the need for immunosuppressive medication. Patients in our study can get up to four transplantations \[[@CR20]\]. The average proportion of patients with full graft function after each transplantation was assumed to be increasing from first to third and fourth transplantation, i.e. from 15% to 70% and then 85% for the third and fourth ones \[[@CR20]\].

The comparator treatment is intensive insulin therapy involves frequent self-monitoring of blood glucose and multiple daily insulin injections, further details are described elsewhere \[[@CR20]\].

Cost-effectiveness analysis {#Sec4}
---------------------------

We conducted a probabilistic and structural sensitivity analysis to investigate the cost-effectiveness of stem cell-based beta cell replacement therapy and to evaluate uncertainty around our results. Our simulation model was a discrete state-transition Markov model, which had a lifetime horizon. Its hypothetical cohort was composed of type 1 diabetes patients with hypoglycemia unawareness in the province of Alberta who fulfill the inclusion criteria to get an islet transplant. The model took the perspective of the provincial healthcare provider and its inputs were the same as in the pre-existing cost-effectiveness model \[[@CR20]\], except for the described variations. Effectiveness was expressed in quality-adjusted life-years (QALYs) to measure the impact of therapy on both quality of life and life expectancy. All monetary estimates are expressed in 2016 Canadian dollars, with necessary adjustments made using the Canadian consumer price index for health and personal care \[[@CR22], [@CR23]\].

We updated model parameters from our pre-existing model of unstable type 1 diabetes \[[@CR20]\] as described below. We model a future technology functioning without the need of immunosuppression. Therefore we had to change the parameters that -- even partially - had to do with this medication. For that we removed all disutilities, costs and probabilities that had only to do with immunosuppression. The parameters for rate, costs and disutility of initial complications were adjusted by lowering each by 40% because this portion was attributed solely to immunosuppression. Specifically the rate changed from 0.65 to 0.39, the cost from \$600 to \$360, and the disutility from 0.05 to 0.03. Further, a study of the impact of type 1 diabetes complications (*N* = 2341) served us to update our utility i.e. quality of life estimates \[[@CR24]\]. Patients in that study were more comparable to our hypothetical cohort than the ones in our original data sources. Yet they were still younger (39.3 vs. 47.0 years old) and with shorter diabetes duration (16.3 vs. 29.4 years) \[[@CR20], [@CR24]\]. Given that new evidence, we included neuropathy in the diabetes-related complications and adjusted our overall estimate for the complications state not only for multiple complications, but also to fit the actual age and duration of diabetes in our cohort \[[@CR2], [@CR24]--[@CR29]\]. The utility parameter in the complications state was therefore adjusted from 0.57 to 0.47.

The cost-effectiveness model was constructed and run with the software TreeAge Pro 2016 (Williamstown, MA, USA). The cost of goods modeling was constructed and run using Microsoft Excel. Costs and benefits were discounted at 3%, and sensitivity analysis were performed at 0% and 5%. These were the rates that had been recommended by the Canadian Agency for Drugs and Technologies in Health \[[@CR30]\]. Half-cycle correction was applied. Our probabilistic analyses used 64,000 iterations for each scenario. We estimated the value of further research reducing the decision uncertainty by way of value-of-information analysis \[[@CR31], [@CR32]\]. We calculated the expected value of perfect information (EVPI) and the expected value of partial perfect information (EVPPI) for the cost of goods group of parameters. For that EVPPI calculation we used nested Monte Carlo simulations with 600 'outer' and 600 'inner' loops. Additional information on our value of information approach, including choice of WTP thresholds, can be found elsewhere \[[@CR20]\].

Integration of cost of goods results {#Sec5}
------------------------------------

To integrate the results of the cost of goods modeling into our cost-effectiveness model, we took the parameter representing the cost per transplantation within the transplant state in the original model, and split it up into non-dose costs and dose costs. Based on literature we assumed the non-dose costs, including the transplant procedure, to be about 38% of the costs per transplantation \[[@CR33]\]. For that parameter of our model we used a Gamma distribution with a relative standard deviation of 10% (i.e. standard deviation as percentage of the mean). For the dose costs, based on our cost of goods (COG) model we used the following equation:$$\documentclass[12pt]{minimal}
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Here dose costs are calculated multiplying the cost of goods upstream by a cost of goods downstream factor and a factor that we called "regulatory burden factor". The cost of goods upstream came from the above described fitted distributions estimating the "pure" production cost of the cells. The downstream factor accounted for the so-called downstream processing, which is necessary after the cells are produced, e.g. cell harvesting, volume reduction, washing, formulation for storage or delivery (see Fig. [2](#Fig2){ref-type="fig"}). We used the regulatory burden factor to account for the possibility of additional regulatory burden due to stricter regulatory requirements for a new cell production process whose product is designed to enter regular healthcare practice.Fig. 2Illustration of cost of goods modeling in a biotechnology application. On the top one can see the different parts that compose the cost of goods for manufactured cell products. The bottom part portraits the upstream cost of goods, highlighted in green, as proportional to the overall cost of the treatment. That is a simplification compared to our analysis, which treats costs after cell product arrival at the hospital as independent from the cost of upstream cell processing

The mean of the cost of goods downstream factor (multiplier) was assumed to be three, four and eight, depending on scenario, based on expert opinion and published literature \[[@CR34]\]. The mean of the regulatory burden factor was assumed to be 1.2 and 1.8 depending on scenario (i.e. 20% and 80% additional costs respectively due to regulation). Both multipliers were made probabilistic using a Log-normal distribution and expert opinion on variation estimates.

Cost of goods modeling {#Sec6}
----------------------

We modeled the cost of goods in Microsoft Excel based on a report describing manufacture of pancreatic progenitors from single cell cultures of hES cells \[[@CR6]\]. Briefly, the modeled process consisted of thawing one or more frozen hES cells vials and expanding them in adherent culture for about 14 days, passaging four times. Then, hES cells were cultured in suspension forming cell clusters, while a cocktail of molecular signals was added to the media to promote stepwise differentiation of hES cells into pancreatic progenitors.

The cost of goods was estimated by adapting a cost minimization decisional tool for this manufacturing process \[[@CR21]\]. The tool selected the optimal set of disposable culture vessels for a user-specified annual demand, lot size, cell dose and user-specified manufacturing constraints, i.e. maximum allowed number of culture vessels per lot, which was set to 100. In its estimation process, the tool calculated the material (i.e. media, disposable culture vessels), labor, quality control and equipment costs involved in the expansion and differentiation stages of the process for a battery of sequential culture vessel combinations (see Fig. [2](#Fig2){ref-type="fig"}). Additional parameters utilized during the cost calculations were the overall yield of the manufacturing process and the expansion fold of the hES cells. In that way the upstream cost of goods were estimated.

The cost minimization decisional tool did not include the downstream component of the manufacturing process (e.g., finishing, packaging, shipping), therefore 95% credible ranges were derived for cost estimates in four different settings: two cell culture methods (adherent and suspension), and each with two supply levels (50 and 500 doses per year) (also see Table [1](#Tab1){ref-type="table"}). The credible ranges were used to fit Gamma distributions, i.e. the lower and upper bounds of the credible ranges for every cost estimate were equated to the values of cumulative density functions (CDF) at values of CDF = 0.025 and CDF = 0.975. The distributions were then used directly in the health economic modeling software.Table 1Credible ranges and fitted distributions for cost of goods upstreamProduction settingRangeGamma distributionCell cultureSupplyLower boundUpper boundMeanRSDShapeRateAdherent50\$21,300\$83,900\$47,44334.00%8.65050.0001823Adherent500\$14,700\$73,800\$38,58539.60%6.37690.0001653Suspension50\$16,900\$54,900\$33,19329.42%11.55350.0003481Suspension500\$10,300\$53,100\$27,53540.20%6.18800.0002247

Scale of manufacturing {#Sec7}
----------------------

We simulated four manufacturing modes: local production (e.g. at one University only), large scale production (one central lab produces all the doses and then ships them to the hospitals), and two scale-out production modes (local and large scale). The scale-out scenarios involved a network of several labs producing their own doses at their respective location but collaborating with each other through sharing expertise and research resources. We simulated one scale-out scenario for local productions and one for large scale productions. The local and large scale production scenarios assume a demand of 50 and 500 doses per year respectively. In general, the scale out approach may engage the capabilities of multiple local institutions and companies. It could, however, also contribute to unequal product quality and an increased overhead costs.

We estimated the long-term capacity to perform device implants in Canada to be 10 clinical centers. That estimate was derived by counting the hospitals on the list of transplant centers by the Canadian Organ Replacement Register in which clinicians performed islet cell transplants or other transplants of at least three different kinds of organs \[[@CR35], [@CR36]\]. We took this as clinical capacity to carry out transplantations of beta cell replacement devices that *do not* require immunosuppression. In the short term there could be two centers, one for Western Canada and one Eastern Canada.

We describe the demand for and composition of the doses of beta cell replacement tissue as follows. The annual demand of beta cell replacement doses was based on the current number of islet cell transplants in Canada and assumed to be 50 per transplant center, which was derived as linear extrapolation of transplant numbers in at the University of Alberta Hospital. Further we presumed the number of lots produced per year is 10, i.e. about one per month, and a minimum of 500 million cells are required per dose. Those numbers were derived from considerations of cell quality loss over time and the production figures above. Based on experience in the biotechnology sector the production assumed one of two production technologies, adherent or suspension cell culture approach, each with optimized production set ups for the two demand options (50 or 500 doses per year).

As a substantial simplification due to the novelty of the membrane technology, we presumed the cost of the device casing without the cells is off-set by reductions in costs through increased ability to plan transplantation times and processes.

Results {#Sec8}
=======

Our analysis shows that the use of stem cells for beta cell replacement therapy can be an effective use of health budget funds. However, there is substantial uncertainty around the costs of this technology. We calculated the expected range of treatment costs for hES cell-based beta cell tissue. Our probabilistic results indicate that currently this technology could be cost-effective at a WTP threshold of \$100,000 per QALY because three scenarios have ICERs substantially below that threshold (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). Specifically the ICERs of scenarios Adh20, Sus19 and Sus20 are \$79,230, \$89,173 and \$60,111 per QALY respectivly. For the 95% Confidence interval values around our results please see in Additional file [1](#MOESM1){ref-type="media"}.Table 2Results for different scenarios using adherent cell culture (means per patient)ScenarioCostBenefitICEREVPIMaximum Partial EVPI Dose CostsIndexProduction modeSupply per facilityCOGd factorRegulatory factorVariation (RSD^a^)StrategyDifferenceStrategyDifferenceWTP per QALY\$50,000\$100,000Scenarios with 3% discount rate Comp1(Comparator 3%)74,23011.12 Adh1Local5041.222.5%629,181554,95113.852.73203,20318422090,957 Adh2Local5041.250.0%628,936554,70713.852.73203,11467719,749135,128 Adh3Local5041.822.5%876,810802,58013.852.73293,8772721143,704 Adh4Local5041.850.0%873,510799,28113.852.73292,6691698061214,930 Adh5Scale out local5031.222.5%504,903430,67313.852.73157,6978711,72569,691 Adh6Scale out local5031.250.0%504,835430,60613.852.73157,673149332,911106,144 Adh7Scale out local5031.822.5%690,050615,81913.852.73225,492112623102,737 Adh8Scale out local5031.850.0%688,524614,29413.852.73224,93343215,297167,801 Adh9Scale out local5081.822.5%1,616,3861,542,15613.852.73564,685019273,576 Adh10Scale out local5081.850.0%1,606,9531,532,72213.852.73561,23191052443,892 Adh11Large scale50041.222.5%536,915462,68513.852.73169,42012711,62178,153 Adh12Large scale50041.250.0%536,730462,50113.852.73169,351150131,043124,247 Adh13Large scale50041.822.5%738,478664,24813.852.73243,225243085117,352 Adh14Large scale50041.850.0%736,541662,31113.852.73242,51649914,700192,416 Adh15Scale out large50031.222.5%435,777361,54813.852.73132,38645324,79263,732 Adh16Scale out large50031.250.0%435,661361,43213.852.73132,344300547,59196,481 Adh17Scale out large50031.822.5%586,704512,47413.852.73187,65082814393,084 Adh18Scale out large50031.850.0%585,166510,93613.852.73187,088111825,291148,572Scenarios with 0% discount rate Comp2(Comparator 0%)113,17516.09 Adh19Local5041.222.5%663,514550,33920.604.51122,159139552,62090,906 Adh20Scale out large50031.222.5%470,111356,93620.604.5179,23011,31530,54063,752Scenarios with 5% discount rate Comp3(Comparator 5%)58,5599.09 Adh21Local5041.222.5%616,693558,13411.182.09267,339061490,973 Adh22Scale out large50031.222.5%423,290364,73111.182.09174,70132639663,730All scenarios used the base case assumptions with the described structural deviations. Cost measure is Canadian dollar (2016). Benefit measure is QALY. All result numbers are rounded and including sampling variation^a^Relative standard deviation (RSD; i.e. SD as percentage of the mean) that was assumed for the two factorsTable 3Results for different scenarios using suspension cell culture (means per patient)ScenarioCostBenefitICEREVPIMaximum Partial EVPI Dose CostsIndexProduction modeSupply per facilityCOGd factorRegulatory factorVariation (RSD^a^)StrategyDifferenceStrategyDifferenceWTP per QALY\$50,000\$100,000Scenarios with 3% discount rate Comp1(Comparator 3%)74,23011.12 Sus1Local5041.222.5%480,575406,34613.852.73148,7905612,12659,158 Sus2Local5041.250.0%479,911405,68013.852.73148,546154135,23292,836 Sus3Local5041.822.5%654,137579,90613.852.73212,3424246488,524 Sus4Local5041.850.0%651,401577,17113.852.73211,34045016,335141,768 Sus5Scale out local5031.222.5%393,796319,56613.852.73117,01430528,62747,474 Sus6Scale out local5031.250.0%393,094318,86413.852.73116,757321553,93776,931 Sus7Scale out local5031.822.5%523,705449,47513.852.73164,58233808466,874 Sus8Scale out local5031.850.0%521,437447,20713.852.73163,752108428,588113,389 Sus9Scale out local5081.822.5%1,172,8781,098,64813.852.73402,287050169,848 Sus10Scale out local5081.850.0%1,163,9741,089,74413.852.73399,026352719295,702 Sus11Large scale50041.222.5%421,724347,49413.852.73127,24059028,37059,316 Sus12Large scale50041.250.0%420,338346,10813.852.73126,733339951,26083,398 Sus13Large scale50041.822.5%565,342491,11213.852.73179,828116978586,421 Sus14Large scale50041.850.0%562,360488,13013.852.73178,736129427,942124,381 Sus15Scale out large50031.222.5%349,649275,41913.852.73100,848166643,13647,205 Sus16Scale out large50031.250.0%349,048274,81913.852.73100,629619264,31264,826 Sus17Scale out large50031.822.5%457,207382,97713.852.73140,23238421,50567,653 Sus18Scale out large50031.850.0%455,948381,71813.852.73139,772266943,714101,004Scenarios with 0% discount rate Comp2(Comparator 0%)113,17516.09 Sus19Local5041.222.5%514,909401,73420.604.5189,173438940,83059,131 Sus20Scale out large50031.222.5%383,981270,80820.604.5160,11126,451768447,205Scenarios with 5% discount rate Comp3(Comparator 5%)56,5589.09 Sus21Local5041.222.5%468,087409,52911.182.09196,1601204259,162 Sus22Scale out large50031.222.5%337,161278,60211.182.09133,44717216,41047,207All scenarios used the base case assumptions with the described structural deviations. Cost measure is Canadian dollar (2016). Benefit measure is QALY. All result numbers are rounded and including sampling variation^a^Relative standard deviation (RSD; i.e. SD as percentage of the mean) that was assumed for the two factors

However, the results also indicate that large-scale production has the best chance of providing affordable graft tissue, as can be seen in scenarios ADh15, Adh16 and Adh20 in Table [2](#Tab2){ref-type="table"}. These scenarios have the highest value for money for this method of cell culture. That means that for a given patient benefit the costs are minimized. For the suspension cell cultures the same scenarios also had the lowest ICERs (see scenarios Sus15, Sus16 and Sus20 in Table [3](#Tab3){ref-type="table"}).

With adherent cell culture all scenarios have ICERs higher than \$100,000 except scenario 'Adh20', which has a 0% discount rate and a supply of 500 doses per year. On the other side all suspension cell culture scenarios also have ICERs higher than \$100,000 except for the scenarios 'Sus19' and 'Sus20', both use a 0% discount rate. Such a low discount rate does value small benefits with a long duration more favorable than a higher discount rate would.

Our finding that use of stem cells for beta cell replacement therapy can be an effective use of health budget funds can be confirmed by the value of information results. The value of information can be seen as both a measure of decision uncertainty as well as an indicator of research investment value \[[@CR31], [@CR32]\]. In Fig. [3](#Fig3){ref-type="fig"} we show the expected value of research into the cost-effectiveness of the technologies under consideration. One can see all per-patient EVPI values do peak at high cost-effectiveness thresholds but there also is considerable value when using for instance a \$50,000 threshold. That means that further research into the cost-effectiveness of this treatment can be worthwhile for Alberta up to these upper limits per patient, even if one uses a strict cost-effectiveness threshold of \$50,000.Fig. 3Expected value of perfect information results. Displayed are results of the value of further research for the scenarios using adherent (top) and suspension (bottom) cell culture techniques. All values are per patient calculations for willingness-to-pay thresholds of up to \$200,000 per additional QALY. One can see the different values between cell culture techniques and between production scenarios within each technique. The dotted lines represent scenarios presuming an 80% increase of costs due to additional regulatory requirements compared to regulations currently in place. Scenarios Adh 20 and Sus 20 use a 0% discount rate

We found uncertainty around the mean outcomes and therefore the need to conduct further research in this kind of disease treatment. This becomes clear when we consider the results in Fig. [3](#Fig3){ref-type="fig"} and the number of patients that could benefit. In Alberta alone there are more than 4000 patients with unstable type 1 diabetes \[[@CR37]--[@CR42]\]. Extrapolating this estimate, one can expect to have about 500,000 patients in North America \[[@CR37]--[@CR43]\]. When comparing those figures with the per patient values in Fig. [3](#Fig3){ref-type="fig"}, one can argue that further research in this area of technology can be a sound investment of health budget funds.

We report the treatment dose costs with the production settings we used for a set of example regulatory and cost of goods downstream factors (Table [4](#Tab4){ref-type="table"}). In this comparison one can see the adherent cell culture with 50 dose per year setting has on average no chance of being cost effective because its mean is much higher than any of the maximum costs. The 'adherent 500' setting can only be cost effective with a 1% (or lower) discount rate, without immunosuppression and only at a less strict threshold of \$100,000. At that threshold and discount rate both the suspension cell culture settings can be cost effective without immunosuppression.Table 4Full dose costs using example cost of goods downstream and regulator factorsProduction settingFactorsFull dose costs^a^Cell cultureSupplyCost of goods downstreamRegulatoryMeanLower rangeUpper rangeAdherent5031.2\$170,795\$76,680\$302,040Adherent50031.2\$138,906\$52,920\$265,680Suspension5031.2\$119,495\$60,840\$197,640Suspension50031.2\$99,126\$37,080\$191,160^a^Means and values at the lower and upper 95% credible range

We report the full dose costs with the production settings we used for a set of example regulatory and cost of goods downstream factors (Table [4](#Tab4){ref-type="table"}). In this comparison one can see that our results point towards an increased efficiency through a) high volume production, and b) use of adherent cell culture technique.

Discussion {#Sec9}
==========

Our results show that the use of stem cells for beta cell replacement therapy can be an effective use of health budget funds. Still, there is substantial uncertainty around the costs of this technology. Both of those findings confirm that methods of cost modeling combined with value-of-information analysis can be useful tools for aiding the prioritization. This especially applies to new healthcare technologies. Estimating the cost of transplant tissue we found it possible for the treatment to be cost-effective at commonly used cost-effectiveness thresholds if it greatly reduces the need for immunosuppression. The value of information as well as other results depend very much on the assumptions in the respective scenarios. Those assumptions include transplantations costs, especially transplant tissue cost of goods and immunosuppression, as well as discount rates.

In near future stem cell therapy could be expanded to a much broader population of type 1 diabetes patients. Currently the expansion of beta cell replacement therapy in general is limited by organ supply and risks of immunosuppression. If outcomes were better than for islet transplantation, i.e. long term euglycemia and insulin independence, the lifetime costs of conventional therapy due to management of diabetes complications would be avoided. That would include costs not considered in this analysis which would fall outside of the budget of the provincial health care service, e.g. costs covered by the federal health budget or costs for the patient's family or private insurance.

Challenges of donor-harvested transplants in Canada {#Sec10}
---------------------------------------------------

Additional challenges of the donor-harvested approach in Canada could lead there to more readiness to adopt a stem cell based therapy approach even with initially higher costs. Among those challenges one needs to consider the relative shortage of organ donations, combined with great geographic distances between donors and the islet processing and transplantation site \[[@CR44]\]. These factors can lead to two kinds of costs of timely organ transport. The monetary costs are sometimes covered by different regional health care services or air lines. Air transport companies are known to occasionally ship donor organs free of charge. Nevertheless non-monetary costs are unavoidable. An example is the cost of organ deterioration from with progressive cold ischemia can mar graft yield later on.

All those costs tend to be less for more densely populated countries, or even regions with different organ donation legislation, which can make a considerable difference in donor availability \[[@CR45]\]. International coordination of donor organ availability could also further increase the efficient use available clinical resources. However, such coordination tends to come with substantial political and practical complexities, which require further research but are beyond the topic of this study.

On efficient treatment delivery {#Sec11}
-------------------------------

While high volume implant production can theoretically be cheaper one needs to weigh that with several considerations regarding demand, clinical capacity and other practical limitations. One of those considerations is that stem cell-derived doses are currently as perishable as the donor derived cells. This means they have to be used within about 12--36 h of completion of the production process.

The difference between stem cell derived tissue and harvested cells is here that one can determine the time when the tissue is ready. Instead of the cell dose coming into the hospital more or less randomly at any time of the day or night, one can time the production process so that the dose or doses arrive at the hospital at a predefined day and time of the day.

In that way one can avoid the additional costs involved in nightly or short notice transplantations. But graft doses still have to be transplanted as quickly as possible. If several doses arrive at the same time it is also the case that all need to be transplanted within a short period of time. That could be accomplished if for example every week or every month 10 doses arrive at a hospital and are then all transplanted into 10 patients within the same day.

For that reason the number of lots produced per year is important. Every time a lot is produced all the doses of the lot have to be used within about one day or else go waste. That is because currently it is not possible to preserve beta cell progenitors over long periods, e.g. via cryo-preservation. In this context, it is advantageous from an economic perspective to produce several lots per year with smaller lot sizes, since it is impossible to transplant for example 500 doses in one day -- even if spread over 10 transplantation centers.

Given the nature of the cells, transporting the patients to a central location -- as is done currently - might be a better idea than transporting the cells to multiple patient hospitals across Canada. That is because transport of patients may actually be more affordable than the sum of: a) the health lost through the certain quality loss in the highly perishable cells through transport duration, b) the monetary costs from transporting the cells on a punctual just-in-time basis, c) the costs of duplication of in-hospital infrastructure and staff training.

Limitations {#Sec12}
-----------

Ongoing breakthroughs for example in current good manufacturing practice (cGMP) and mass cell expansion and limit the longevity of our estimates and modeling efforts. Breakthroughs include the genetic engineering technique CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat) and the use of modern bioreactors which aid various kinds of bioprocessing \[[@CR46], [@CR47]\]. All those technologies have great influence on the capacities of researchers to generate new or more affordable ways of producing transplantable tissue.

We acknowledge that intensive insulin therapy as only comparator strategy to stem cell-based beta cell replacement therapy did limit the scope of our results. However, we consider the comparator and hypothetical patient cohort in our model to be appropriate because of the patient population under consideration. We explicitly limit our study population to patients who: 1) do not have the degree of major comorbidities which would justify risks of whole organ transplantation, 2) are on intensive insulin treatment and 3) are candidates for islet transplantation. Still, we think further studies in a North American context do need to include donor-base islet transplantation as one of the comparators. Other donor-based approaches to address type 1 diabetes could also be integrated.

The cost of the semi-permeable membrane in which the cells are enclosed had to be estimated doe to lack of data. This and the fact that we did not change the follow up costs and frequency compared to the study on islet transplantation are clear limitations of this study. However, in light of the technology under consideration being new and containing living cell tissue, the differences between the actual and our estimated follow-up costs are likely smaller than for a less complex implant device.

We expect that implantation would likely be an outpatient procedure with much more limited risks compared to islet transplantation, or even whole organ transplantation. In this study we presumed the new treatment technology would still be require an in-patient procedure including four days of hospital stay. Compared to that estimate, an out-patient procedure would further reduce the costs of stem cell-based beta cell replacement therapy while increasing patient quality of life.

One of the main goals of using re-extractable sheets for transplantation, instead of the standard cell injection into the liver, is to shield the cells from being attacked by the immune system. Since this is an early health technology assessment of a very new technology we made the assumption that this goal can be achieved without the use of imunosuppressive drugs. If future developments show that this is not the case then immunosuppression would be necessary and with it would come the usual costs and side effects as mentioned elsewhere \[[@CR20]\].

Conclusions {#Sec13}
===========

Using new grafts substantially increased the value of research into beta cell replacement therapy, especially when also addressing the need for immunosuppression. Such a technology can improve treatment access and quality of life for patients through increased graft supply and protection. Stem cell-based implants can be a feasible way of treating a wide range of patients with type 1 diabetes.

Additional file {#Sec14}
===============

Additional file 1:95% Confidence Interval of Results. We report the 95% confidence interval for the costs and benefits of all our scenarios and the ICERs that were calculated from those values. (PDF 60 kb)

cGMP

:   Current good manufacturing practice

COG

:   Cost of goods

CRISPR

:   Clustered Regularly Interspaced Short Palindromic Repeat technology, a genome editing tool

EVPI

:   Expected value of perfect information

EVPPI

:   Expected value of partial perfect information

hES cells

:   Human embryonic stem cells

ICER

:   Incremental cost-effectiveness ratio

QALY

:   Quality-adjusted life-year

RSD

:   Relative standard deviation

SD

:   Standard deviation

Wtp

:   Willingness to pay per additional QALY
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